Search for content, post, videos
Advertisement

He is the new CEO of SmartCella

SmartCella Holding has announced that Niklas Prager has been appointed as the new CEO.

“Niklas has a perfect background for SmartCella. He has experience from the global pharma industry and has also led projects that fundamentally transformed pharmaceutical companies through creative ideas and great determination. With Niklas as CEO, we intend to accelerate our expansion, and this will mark the beginning of SmartCella’s next era. The fact that Niklas has had so many different roles in his career, both operational and as an advisor, is a fantastic asset for us given all the different stakeholders the company has within both big pharma, medtech, biotech, and throughout the entire research field. He will be an inspiring leader of a competent team of employees from over 22 countries,” says Christian Kinch, Chairperson of SmartCella Holding.

Niklas Prager

Niklas Prager has extensive and solid experience from the global pharma industry and has held leadership positions in research-focused pharmaceutical companies such as Merck/MSD and Pfizer, with both Sweden and the USA as a base. He has also been CEO and board member/chairperson of several medtech and biotech companies such as Medivir AB and CellaVision AB, and has experience with different types of ownership, from listed to private and private equity.

Prager is 52 years old and holds a Master of Science in Business Administration from the Stockholm School of Economics and has also studied in the MBA program at the University of Michigan.

“SmartCella is a truly unique company. Its strength lies in the combination of a commercializable medical device for the delivery of targeted treatments to organs and tumors where the medical need is enormous, and world-leading cell and gene therapy with both treatments and new methods for the administration of such treatments, where the agreement with AstraZeneca validates the technology.”

“SmartCella is a truly unique company. Its strength lies in the combination of a commercializable medical device for the delivery of targeted treatments to organs and tumors where the medical need is enormous, and world-leading cell and gene therapy with both treatments and new methods for the administration of such treatments, where the agreement with AstraZeneca validates the technology. Sweden once again has a company at the forefront of the booming niche of global drug research. The potential to radically change the treatment of serious illnesses is staggering, and I cannot imagine a better opportunity to be a part of and influence the future for seriously ill patients. I look forward to taking over the baton and embarking on the next step in SmartCella’s development together with the board, management, and staff. Both the company and the board have an impressive mix of medical and entrepreneurial expertise with a strong track record, and I am confident in what SmartCella can achieve,” says Niklas Prager.

Niklas will assume the role of CEO during the summer of 2023.

Photo of Niklas Prager: SmartCella

Advertisement